David Rohlf, MD
Urology · Davenport, IANPI 1912900820
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (52.9%), food and beverage and gifts — rather than concentrated in one kind of arrangement. Medtronic accounts for 66.6% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $1,851 and has fallen 98.3% since, to $31 in 2025.
Across 42 payments — averaging $64.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Tosoh Bioscience, Inc.$239
- Coloplast$128
- AbbVie$103
- Johnson & Johnson$100
- Axonics, Inc.$97
- plus $242 from 10 others
What the payments were for
- Travel & lodging$1,44353%
- Food & beverage$93634%
- Education$1104%
- Gifts$2399%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 15 | $1,818 |
| Tosoh Bioscience, Inc. | 1 | $239 |
| Coloplast | 1 | $128 |
| AbbVie(2 entities) | 6 | $103 |
| Johnson & Johnson | 1 | $100 |
| Axonics, Inc. | 4 | $97 |
| Endo Pharmaceuticals Inc. | 1 | $64 |
| Dendreon Pharmaceuticals LLC | 2 | $50 |
| Healthtronics Stone Solutions, LLC | 1 | $29 |
| Isoray, Inc | 1 | $29 |
| Progenics Pharmaceuticals, Inc. | 1 | $17 |
| 180 Medical, Inc. | 1 | $17 |
| Amgen | 1 | $13 |
| Urovant Sciences Inc | 1 | $13 |
| Travere Therapeutics, Inc. | 4 | $10 |
| Ambu Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$1,499
- PA, ST AIA-PACK$239
- TITAN$128
How this compares
$2,728 in reported general payments places this provider in the 55th percentile of 114 urology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 99 | $55,145 |
| MyrbetriqMirabegron | 73 | $46,671 |
| Tamsulosin Hcl | 501 | $6,193 |
| Tolterodine Tartrate ErTolterodine Tartrate | 21 | $2,466 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 150 | $2,033 |
| Oxybutynin Chloride | 73 | $1,835 |
| Finasteride | 165 | $1,798 |
| Oxybutynin Chloride ErOxybutynin Chloride | 121 | $1,717 |
| NitrofurantoinNitrofurantoin Macrocrystal | 44 | $1,613 |
| Cephalexin | 203 | $1,391 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 13 | $1,340 |
| Silodosin | 12 | $1,253 |
| Solifenacin Succinate | 13 | $1,030 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 70 | $586 |
| Potassium Citrate ErPotassium Citrate | 11 | $466 |
Paid to pharmacies, not to this prescriber.
Other urology in Davenport
- Ghasoub HarbDavenport$14K
- Mark MillemanDavenport$2K
- Matthew BreamDavenport$1K
- Vignesh PackiamIowa City$112K
- Annah VollstedtIowa City$66K
- Bradley EricksonIowa City$65K
- Michael OdonnellIowa City$62K
- Kevin BirusinghDes Moines$59K
- Ryan DornbierClive$55K
- Alexandria HertzIowa City$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.